



## Faculty Disclosures

*The following types of relationships may be deemed relevant include:*

1. *Advisor or review panel member*
2. *Consultant*
3. *Employee*
4. *Officer or Board Member*
5. *Grant/research support*
6. *Speaker/honoraria includes speakers bureau, symposia, and expert witness*
7. *Independent contractor*
8. *Executive role and/or ownership interest*
9. *Royalties and/or patient beneficiary*
10. *Intellectual property/patents*
11. *Stock options or bond holdings in a for-profit corporation or self-directed pension plan*
12. *Private investigator*
13. *Expert witness*
14. *Equity interest*
15. *Other: specify details*

*All of the relevant financial relationships listed for the meeting faculty have been mitigated.*

### **Bolster, Marcy, MD**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Faculty/Planner

Disclosure: Prometheus, 5 (Ongoing)

### **Dua, Anisha, MD, MPH**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Moderator

Disclosure: AbbVie/Abbott, 2 (Ongoing); Amgen, 1 (Ongoing), 2 (Ongoing); AstraZeneca, 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Sanofi, 1 (Ongoing), 2 (Ongoing)

### **Ferreira, Carlos**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

**Koenig, Curry, MD, MS**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Session Coordinator

Disclosure: Amgen, 1 (Ongoing), 6 (Ongoing)

**Langford, Carol, MD, MHS**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Speaker

Disclosure: AbbVie, Non-paid consultant (Ongoing); AstraZeneca, 5 (Ongoing), Non-paid consultant (Ongoing);

Bristol-Myers Squibb(BMS), 5 (Ongoing), Non-paid consultant (Ongoing); GlaxoSmithKlein(GSK), 5 (Ongoing)

**Oquendo, Clarissa**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

**Quinn, Kaitlin, MD, MHS**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

**Ross, Sharon**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

**Seo, Phillip, MD**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Speaker

Disclosure: Amgen, 1 (Ongoing)

**Scipio, Cheyenne**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

**Stanley, Myria, MS, DES**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

**Volkman, Elizabeth, MD, MS**

Scientific Session: ACR Convergence Replay 2024: Controversies in the Treatment of ANCA-Associated Vasculitis

Role: Clinical Chair

Disclosure: Boehringer-Ingelheim, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing);

GlaxoSmithKlein(GSK), 2 (Ongoing); Horizon, 5 (Ongoing); Prometheus, 5 (Ongoing)